{"filings":[{"id":2164758,"accession_number":"0001193125-26-342695","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-08-10T21:19:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cogent Biosciences launches $400M at-the-market equity offering via Guggenheim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Aug 10, 2026 to sell up to $400M of common stock under ATM sales agreement with Guggenheim Securities.","Offering uses automatic shelf registration on Form S-3ASR filed Nov 7, 2025; shares sold at market prices.","Gibson, Dunn & Crutcher issued legal opinion on the shares, filed as exhibit to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2144720,"accession_number":"0001193125-26-341315","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-08-10T12:06:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent reports Q2 net loss $96.4M; bezuclastinib PDUFA dates set for Nov/Dec 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.4M vs $73.5M in Q2 2025; R&D $70.8M, G&A $31.8M.","Cash $792.3M at June 30, 2026; pro forma $865.9M with $73.6M ATM proceeds, funds into late 2028.","FDA accepted NDA for bezuclastinib+sunitinib in GIST with priority review; PDUFA Nov 30, 2026.","AdvSM NDA submitted June 30; NonAdvSM PDUFA Dec 30, 2026; APEX trial 65% ORR.","PEAK trial: HR 0.50, mPFS 16.5 vs 9.2 months, ORR 46% vs 26%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000323,"accession_number":"0001193125-26-267566","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-06-11T20:15:05+00:00","items":["5.07"],"status":"ready","headline":"Cogent shareholders elect three directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director nominees elected: Chris Cain (124.4M votes for), Arlene Morris (120.2M for), Todd Shegog (124.1M for).","Ratification of PwC as independent auditor: 154.0M for, 399K against, 33.6K abstentions.","Advisory vote on executive compensation approved: 129.2M for, 13.98M against, 32.6K abstentions.","Meeting held June 9, 2026; record date April 13, 2026 with 170.8M shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94144,"accession_number":"0001193125-26-205124","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $97.4M; cash $866.4M to fund into 2028; NDA for bezuclastinib in GIST under FDA review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $97.4M for Q1 2026 vs $72.0M Q1 2025; R&D spend $75.4M, G&A $28.2M.","Cash, equivalents and marketable securities $866.4M as of March 31, 2026, expected to fund operations into 2028.","FDA has accepted NDA for bezuclastinib in NonAdvSM (PDUFA Dec 30, 2026); NDA for GIST submitted under RTOR with Breakthrough Therapy designation.","Pivotal Phase 3 PEAK trial data in GIST selected for oral presentation at 2026 ASCO annual meeting on May 30.","Inducement grants of options for 62,600 shares and 48,600 RSUs awarded to seven new employees on April 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106311,"accession_number":"0001193125-26-053131","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.","PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.","Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.","Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.","Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122623,"accession_number":"0001193125-25-311217","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent reports positive SUMMIT and APEX trial results for bezuclastinib in mastocytosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT Part 2: mean TSS change -24.3 (-43%) vs placebo -15.4 (-29%), p<0.001; 34.3% vs 18.1% had >=50% TSS reduction (p=0.01).","SUMMIT: 87.4% had >=50% serum tryptase reduction; 75.6% had >=50% bone marrow mast cell reduction (p<0.001 vs placebo).","APEX Part 2 top-line: 57% ORR (CR+CRh+PR+CI) per mIWG criteria; 80% ORR per pure pathological response.","APEX: 89% had >=50% serum tryptase reduction; 91% had >=50% KIT D816V VAF reduction; no discontinuations due to TRAEs.","Cogent expects to submit NDA for bezuclastinib in AdvSM to FDA in H1 2026; detailed APEX data at scientific meeting H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122622,"accession_number":"0001193125-25-286158","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cogent completes $230M 1.625% convertible senior notes offering due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.","Notes bear 1.625% interest payable semiannually on May 15 and Nov 15, starting May 15, 2026; mature Nov 15, 2031.","Initial conversion rate 22.2469 shares per $1,000 principal (conversion price ~$44.95); settlement in cash, stock, or combo at company's election.","Notes are senior unsecured obligations; redeemable at company's option after Nov 20, 2029 subject to stock price conditions.","Noteholders may require repurchase upon a Fundamental Change (e.g., business combination, delisting) at principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122621,"accession_number":"0001193125-25-278679","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cogent Biosciences prices 9.7M share offering at $31 and $230M 1.625% convertible notes due 2031 for ~$475M net","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Equity offering of 9,677,420 shares at $31.00 per share, upsized from $200M, with underwriters exercising over-allotment for additional 1,451,613 shares.","Convertible notes offering of $200M aggregate principal (upsized to $230M) of 1.625% senior notes due 2031, conversion premium ~45% above equity offering price.","Combined net proceeds expected ~$475.3M, to be used to repay $50M term loan and fund development/commercialization of bezuclastinib.","Offerings led by J.P. Morgan, Jefferies, Leerink Partners, and Guggenheim Securities for equity; Jefferies and J.P. Morgan for notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122620,"accession_number":"0001193125-25-273315","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cogent: bezuclastinib combo reduces progression risk by 50% in Phase 3 GIST trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEAK trial met primary endpoint: HR 0.50 (95% CI: 0.39–0.65) for progression-free survival.","Median PFS 16.5 months (bezuclastinib + sunitinib) vs 9.2 months (sunitinib alone).","Objective response rate 46% (combo) vs 26% (sunitinib), safety generally manageable.","Company plans NDA submission for NonAdvSM by end 2025; GIST NDA in H1 2026.","Top-line APEX AdvSM trial results expected December 2025; ASH presentations upcoming."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122619,"accession_number":"0001193125-25-261797","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.","Net loss of $80.9M (Q3 2025) vs $70.6M (Q3 2024); R&D expenses $69.0M.","Phase 3 PEAK (GIST) top-line results expected Nov 2025; APEX (AdvSM) in Dec 2025.","NDA filing for NonAdvSM on track for year-end 2025; Breakthrough Therapy Designation granted for bezuclastinib.","Raised $215.8M net from public offering and $39M from ATM since July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139327,"accession_number":"0001193125-25-201353","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cogent Biosciences signs 7yr10mo lease for new Waltham HQ at $32/sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases 31,518 sq ft at 180 Third Avenue, Waltham, MA as new corporate headquarters, replacing existing HQ.","Term of 7 years 10 months starting expected May 2026; initial rent $32/sq ft with $1/sq ft annual increases.","Rent abatement for first 5 months; security deposit of ~$336,000 via letter of credit.","One option to extend lease for an additional 5 years.","Landlord performing turnkey buildout; no material tenant improvement costs for Cogent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139326,"accession_number":"0000950170-25-102433","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent reports positive SUMMIT trial, Q2 net loss $73.5M; pro-forma cash $453M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SUMMIT trial met primary endpoint: TSS improvement 8.91 points vs placebo (p=0.0002); 87.4% bezuclastinib patients had ≥50% tryptase reduction.","Upcoming milestones: PEAK and APEX top-line results in 2H 2025; NDA submission by end of 2025.","Q2 net loss $73.5M (vs $59.0M YoY); R&D $62.2M; G&A $13.4M; cash $237.8M at June 30, 2025.","Pro-forma cash $453M including $215.8M net from July upsized offering; $400M debt facility with SLR Capital.","Inducement grants to 6 new employees: 172,450 options at $9.00, 10-yr term, 4-yr vest."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139325,"accession_number":"0001193125-25-157390","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Bezuclastinib SUMMIT trial beats all primary/secondary endpoints; NDA submission by end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT trial met primary endpoint: mean TSS reduction of 24.3 vs 15.4 placebo (p=0.0002); 8.91-point placebo-adjusted improvement.","87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% placebo (p<0.0001).","NDA submission to FDA expected by end of 2025; plan to present full data at medical meeting.","Raised ~$230M gross via offering of 22.2M shares at $9 (plus underwriter option fully exercised).","Cash balance ~$237M as of June 30, 2025; access to up to $350M via debt facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139324,"accession_number":"0001193125-25-155811","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent reports positive top-line results from SUMMIT trial of bezuclastinib in non-advanced systemic mastocytosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT Part 2 met primary endpoint with highly significant mean TSS reduction of 24.3 points vs placebo 15.4 (p=0.0002) at 24 weeks.","87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% on placebo (p<0.0001).","All key secondary endpoints achieved statistical significance, including KIT D816V VAF and bone marrow MC aggregates reductions.","Company on track to submit NDA to FDA for bezuclastinib in NonAdvSM by end of 2025; detailed results planned for medical meeting.","Safety profile manageable: most TEAEs low grade, discontinuations due to ALT/AST elevations (5.9%) all resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156906,"accession_number":"0001193125-25-138813","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Cogent Biosciences secures up to $400M non-dilutive debt facility; $50M drawn at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M credit facility from SLR; first tranche of $50M funded on June 11, 2025.","Interest rate: 4.75% + greater of 1-month SOFR or 4.15%; matures June 1, 2030.","Future tranches tied to milestones: $25M after positive SUMMIT data, $75M after positive PEAK data.","$50M additional upon $85M net product revenue on trailing 6 months by June 30, 2027; $200M mutual.","Proceeds for working capital; monthly interest-only until June 1, 2028, with possible deferral to 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156905,"accession_number":"0001193125-25-135337","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Cogent stockholders approve officer exculpation; annual meeting results filed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Approved amendment to certificate of incorporation to exculpate officers: 86,181,373 for, 4,422,462 against.","Re-elected directors Karen Ferrante (68,418,781 for) and Matthew E. Ros (77,274,345 for).","Ratified PricewaterhouseCoopers as auditor with 101,115,649 votes for.","Advisory vote on executive compensation approved: 89,797,699 for, 808,715 against.","Company presenting at Jefferies Global Healthcare Conference on June 5, 2025 (details in corporate presentation)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156904,"accession_number":"0000950170-25-063987","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.","Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.","Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.","Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.","Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175287,"accession_number":"0000950170-25-026103","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.","Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.","Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.","NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.","Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192239,"accession_number":"0001193125-24-273393","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent Biosciences reports positive Phase 2 bezuclastinib data in AdvSM and NonAdvSM at ASH 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APEX (AdvSM): 52% ORR per mIWG-MRT-ECNM; 61% in TKI-naïve; 83% at 100 mg BID. Median PFS not reached; 24-mo PFS rate 82%.","100% PPR ORR at 100 mg BID; 94% of patients had >=50% tryptase reduction; 93% had >=50% KIT D816V VAF reduction.","SUMMIT (NonAdvSM): 56% mean TSS improvement; 76% of patients had >50% MS2D2 reduction; 49% mean MC-QoL improvement at 24 wks.","95% of patients with baseline tryptase >=20 ng/mL achieved <20 ng/mL by week 24; 84% with baseline >11.4 ng/mL achieved <11.4.","SUMMIT Part 2 enrollment complete (179 patients); top-line expected July 2025. APEX Part 2 enrollment completion Q1 2025; top-line mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192238,"accession_number":"0000950170-24-124653","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.","Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.","Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).","Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.","Inducement grants of options to purchase 132,350 shares to three new employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208722,"accession_number":"0001193125-24-211584","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.","Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.","SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.","Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.","Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208721,"accession_number":"0000950170-24-091220","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q2 2024 net loss $59.0M; cash $389.9M; trial enrollment on track for 2025 readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.","Net loss $59.0M for Q2 2024, compared to $44.1M in Q2 2023; R&D expenses $54.3M.","Enrollment in SUMMIT, PEAK, APEX registration-directed trials on track; topline results expected from all three in 2025.","Appointed Cole Pinnow as Chief Commercial Officer; initiated IND-enabling studies for CNS-penetrant ErbB2 program.","Plan to initiate Phase 1 trial for FGFR2 inhibitor in H2 2024; IND-enabling studies for PI3Ka program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226457,"accession_number":"0001193125-24-169756","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).","SUMMIT Part 2 enrollment on track to complete Q2 2025; top-line results expected by end of 2025.","APEX study (Advanced SM) enrollment to complete end of 2024; top-line results mid-2025.","PEAK study (GIST) enrollment expected to complete Q3 2024; top-line results by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226456,"accession_number":"0001193125-24-155116","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cogent Biosciences shareholders approve doubling authorized common stock to 300M shares","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Amendment increases authorized common shares from 150M to 300M; total authorized shares from 160M to 310M.","Outdated reverse stock split provisions deleted from the certificate of incorporation.","All three director nominees elected; Andrew Robbins received 67.8M for, Peter Harwin received 51.7M for.","Advisory vote on executive compensation passed with 69.6M for vs 6.7M against; future votes set for annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226455,"accession_number":"0000950170-24-053974","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.","Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).","Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.","Completed oversubscribed private placement yielding $213.4M net proceeds.","Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245466,"accession_number":"0001193125-24-074628","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Cogent Biosciences exchanges 8.3M common shares for Series B non-voting convertible preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8,300,000 common shares exchanged for 8,300 Series B Preferred convertible into 20,580,000 common shares.","Exchange closes March 25, 2024; Series B has no voting rights except on amendments to its preferences.","Post-exchange common outstanding: 95,613,396; Series A Preferred convertible into 18,616,250 common shares.","Issued under Section 3(a)(9) exemption; no registration required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245465,"accession_number":"0000950170-24-019754","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.","Cash $273.2M at Dec 31, 2023; $225M PIPE closed Feb 2024 at $7.50/share (37% premium); pro-forma $487M funds into 2027.","Three registration-directed bezuclastinib trials enrolling: SUMMIT (NonAdvSM), APEX (AdvSM), PEAK (GIST); topline results expected in 2025.","SUMMIT Part 1b data: 51% mean TSS improvement, 70% of patients with ≥50% improvement; 100 mg RP2D selected.","PEAK lead-in: 33% confirmed ORR in 2nd-line GIST; bezuclastinib+sunitinib combination well-tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245464,"accession_number":"0001193125-24-035203","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","5.03","3.02","7.01","9.01"],"status":"ready","headline":"Cogent Biosciences raises $225M in oversubscribed PIPE at $7.50/share, 37% premium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $225M from 17.7M common shares at $7.50 and Series B convertible preferred.","Pro-forma cash expected to fund into 2027 through SUMMIT, PEAK, and APEX registration trials.","Led by Commodore Capital; includes Fairmount, Redmile, Janus, TCGX, Adage, Venrock, Deerfield, Perceptive.","Investor webcast on Feb 23 to review SUMMIT Part 1b data at AAAAI annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262944,"accession_number":"0001193125-23-292084","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent reports positive Phase 2 bezuclastinib data in systemic mastocytosis at ASH 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT Part 1a: 100% of bezuclastinib patients achieved ≥50% reduction in serum tryptase vs 0% on placebo; 100% achieved ≥50% reduction in KIT D816V VAF.","APEX Part 1: 52% ORR per mIWG-MRT-ECNM criteria (56% in TKI-naïve); 75% PPR ORR (86% in TKI-naïve).","Safety: no related cognitive impairment or bleeding events; most AEs low grade and reversible.","SUMMIT Part 2 (registration-directed) to start H1 2024; APEX Part 2 (~65 patients) enrollment on track for end of 2024.","100% of bezuclastinib patients in SUMMIT with measurable baseline mast cell aggregates achieved ≥50% reduction in bone marrow mast cell burden vs 14% placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262943,"accession_number":"0000950170-23-057785","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q3 net loss $55.4M; cash $312.8M providing runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.4M for Q3 2023 vs $35.1M in Q3 2022; R&D expenses $50.1M (up 67% YoY).","Cash, cash equivalents and marketable securities $312.8M as of Sept 30, 2023, down from $350.9M at June 30, 2023.","SUMMIT NonAdvSM trial Part 1 enrollment completed at 54 patients; Part 2 registration-directed trial to begin 1H 2024.","APEX AdvSM trial Part 2 enrollment on track to complete by end 2024; SUMMIT Part 1a data selected for oral presentation at ASH 2023.","PEAK Phase 3 GIST study lead-in data shows 33% ORR in 2nd-line; Phase 3 enrollment on track by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280141,"accession_number":"0000950170-23-039389","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.","Net loss Q2 2023: $44.1M vs $34.9M Q2 2022; R&D $38.9M vs $29.5M.","Phase 3 PEAK lead-in data: 55% DCR; 100% DCR and 17% ORR in evaluable 2nd-line GIST patients.","Selected FGFR2 kinase inhibitor as first internally developed candidate; preclinical data planned for 2H2023.","Initial SUMMIT (NonAdvSM) and updated APEX (AdvSM) data expected in second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298654,"accession_number":"0001193125-23-163546","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cogent Biosciences prices $150M common stock offering of 12.5M shares at $12.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers 12,500,000 shares of common stock at $12.00 per share; gross proceeds ~$150M.","Underwriters granted 30-day option to purchase up to 1,875,000 additional shares on same terms.","Underwriting syndicate led by J.P. Morgan, Jefferies, Piper Sandler, and Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298653,"accession_number":"0001193125-23-162557","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cogent Biosciences stockholders approve 6M share increase under 2018 Equity Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three director nominees elected: Chris Cain, Arlene Morris, Todd Shegog each received >51% of votes cast.","Proposal to increase shares reserved under 2018 Stock Option Plan by 6,000,000 shares passed with 40,805,846 for, 23,427,202 against.","Ratification of PricewaterhouseCoopers as independent auditor approved with 65,536,975 votes for, 26,688 against.","Record date April 10, 2023: 70,946,790 shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298652,"accession_number":"0001193125-23-161596","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.","In 2nd-line Part 1a: 100% disease control rate and 17% overall response rate.","Safety profile well-tolerated; 2 discontinuations due to AEs; low Grade ≥3 events.","Part 2 enrollment ongoing (target ~388 2nd-line GIST patients); SUMMIT/APEX data expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298651,"accession_number":"0000950170-23-019162","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss widens to $38.6M; cash $220.3M, runway into 2025; AdvSM trial expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $220.3M at March 31, 2023, down from $259.3M at Dec 31; funding expected into 2025.","Net loss of $38.6M for Q1 2023 vs $30.6M in Q1 2022; R&D expenses $36.0M (+41% YoY) driven by clinical trials.","Initiated Part 2 of Phase 2 APEX trial in Advanced Systemic Mastocytosis at 150 mg; enrollment target by end-2024.","FDA granted Orphan Drug Designation for bezuclastinib in mastocytosis (including SM); ~30,000 annual US diagnoses.","Upcoming data: PEAK GIST lead-in safety/efficacy at ASCO June 2023; SUMMIT NonAdvSM and APEX Part 1 data in 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318849,"accession_number":"0000950170-23-007717","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports FY2022 net loss $140.2M, cash $259.3M; outlines bezuclastinib milestones for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.","Cash, equivalents and marketable securities $259.3M as of Dec 31, 2022; runway into 2025.","APEX Part 2 initiation planned mid-2023; updated Phase 3 PEAK lead-in data expected 1H23.","Initial SUMMIT Phase 2 data in nonadvanced systemic mastocytosis expected 2H23.","Appointed Rachael Easton, M.D., Ph.D., VP Head of Clinical Development; Sylvia Adams to SAB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337083,"accession_number":"0001193125-22-302302","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cogent Biosciences reports 89% ORR in TKI-naive AdvSM patients from Phase 2 APEX trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["89% ORR in TKI-naïve patients; 73% ORR in all evaluable patients (median 27-week follow-up).","First confirmed CR at 20 weeks; 77% with ≥2 cycles had complete clearance of bone marrow mast cell aggregates.","No related cognitive effects or intracranial bleeding; favorable safety profile with mostly Grade 1/2 events.","Median age 69 years; subtypes: ASM (3), SM-AHN (12), MCL (1); 3 had prior avapritinib/midostaurin.","Plans to present initial PEAK lead-in data H1 2023 and SUMMIT data H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337082,"accession_number":"0000950170-22-024675","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.","Cash & securities $289.1M as of Sep 30, 2022; cash runway expected into 2025.","Phase 3 PEAK trial of bezuclastinib + sunitinib in second-line GIST patients initiated.","Optimized bezuclastinib formulation shows >40% exposure improvement; potential patent protection to 2043.","G&A expense $6.9M vs $5.0M YoY; non-cash stock comp included."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354443,"accession_number":"0000950170-22-015744","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.","Net loss $34.9M for Q2 2022 vs $16.5M in Q2 2021; R&D expenses rose to $29.5M from $12.4M on trial costs.","Positive initial bezuclastinib APEX data: all 11 AdvSM patients achieved ≥50% serum tryptase reduction; no edema, cognitive effects or intracranial bleeding.","On-track for further APEX data by end of 2022; SUMMIT and PEAK trial data expected in 1H2023.","Appointed Fang Fang, Ph.D., as VP Biometrics; she brings over 20 years industry experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372407,"accession_number":"0001193125-22-175601","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K/A","filed_at":"2022-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.","Net proceeds to fund development and commercial activities for bezuclastinib and other candidates.","Underwriters exercised in full their option to purchase 2,730,000 additional shares.","Pre-funded warrants exercisable at $0.01 per share, subject to 9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372411,"accession_number":"0001193125-22-174885","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cogent Biosciences raises ~$162M in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 15,169,698 shares at $8.25 per share plus pre-funded warrants for 3,030,302 shares at $8.24.","Underwriters exercised option to purchase an additional 2,730,000 shares on same terms.","Gross proceeds of approximately $162 million before underwriting discounts and expenses.","Pre-funded warrants exercisable immediately; holder cannot exceed 9.99% beneficial ownership without notice.","Offering made under effective shelf registration statement filed May 24, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372410,"accession_number":"0001193125-22-171489","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Cogent announces positive initial Phase 2 APEX data for bezuclastinib in advanced systemic mastocytosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.","All 8 evaluable patients had ≥50% bone marrow mast cell reduction; six cleared aggregates.","No periorbital/peripheral edema, cognitive effects, or intracranial bleeding reported.","Two prior avapritinib patients showed similar benefit; all remained on study at cutoff.","Company to accelerate timelines; next APEX update by end of 2022; SUMMIT data in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372409,"accession_number":"0001564590-22-019075","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $30.6M; cash $191M funds into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.6M in Q1 2022 vs. $11.7M in Q1 2021; R&D spend $25.5M (up from $8.2M).","Cash & equivalents $191.0M as of March 31, 2022, compared to $219.7M at year-end 2021.","Initial APEX Phase 2 data for bezuclastinib in AdvSM to be presented at EHA June 2022.","FGFR2 inhibitor advancing toward IND in H2 2023; ErbB2 mutant selective program announced.","SUMMIT (NonAdvSM) and PEAK (GIST) trials actively enrolling patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372408,"accession_number":"0001193125-22-143689","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Cogent Biosciences terminates $75M ATM equity offering agreement with SVB Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Sales Agreement with SVB Securities LLC (f/k/a SVB Leerink) for an at-the-market offering program.","The ATM allowed the company to sell up to $75 million of common stock at its sole discretion.","Termination effective May 5, 2022; the facility is no longer available for use.","Original agreement was entered into on February 8, 2021 and filed as Exhibit 1.2 to the S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391251,"accession_number":"0001564590-22-010231","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.","APEX Phase 2 trial in AdvSM on track for initial data in H1 2022; SUMMIT (NonAdvSM) and PEAK (GIST) actively enrolling.","Raised ~$38M via ATM in Q4 2021; shares sold at $9.25-$10.30.","R&D expenses $55.9M in FY2021 vs $25.7M in FY2020, driven by trial start-up costs and research team expansion.","Appointed Dr. Zamaneh Mikhak as SVP Head of Clinical Development; R&D Investor Event on April 8, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409433,"accession_number":"0001193125-21-367000","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cogent updates employment agreements for CFO and CMO; salary and bonus unchanged","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO John Green base salary remains $415,500; target bonus 40% of base.","CMO Jessica Sachs base salary remains $460,000; target bonus 40% of base.","Non-CIC severance: 12 months base, pro-rata bonus, 9 months COBRA, 9-month equity acceleration.","CIC severance within 12 months: 12 months base, 100% target bonus, 12 months COBRA, full equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409432,"accession_number":"0001564590-21-055942","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q3 net loss $19.1M; initiates SUMMIT Phase 2, cash $202.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M in Q3 2021 vs $50.0M in Q3 2020 (prior included $46.9M asset acquisition charge).","Cash and equivalents $202.9M; expected to fund operations into 2024.","Initiated SUMMIT Phase 2 trial for bezuclastinib in nonadvanced systemic mastocytosis.","APEX Phase 2 trial for AdvSM on track for preliminary data readout H1 2022.","Appointed Dana Martin as Chief Patient Officer and Courtney Watson as VP Clinical Development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428368,"accession_number":"0001193125-21-246896","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q2 net loss $16.5M; cash $218.1M; initiates Phase 2 APEX trial for bezuclastinib in AdvSM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.5M for Q2 2021 vs $7.4M in Q2 2020; R&D spend $12.4M, G&A $4.9M.","Cash and equivalents $218.1M as of June 30, 2021; expects runway into 2024.","Phase 2 APEX open-label study of bezuclastinib in Advanced Systemic Mastocytosis initiated; preliminary data expected 1H 2022.","SUMMIT Phase 2 study in NonAdvSM on track to start 2H 2021 after positive FDA interactions.","FDA granted orphan drug designation for bezuclastinib in GIST; new study with sunitinib planned 2H 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428367,"accession_number":"0001193125-21-211800","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2021-07-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cogent Biosciences signs 12-year lease for 38,075 sq ft lab/office space in Boulder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases ~38,075 RSF at 4840 Pearl East Circle, Boulder, CO; 14 months free rent followed by 12-year term.","Landlord provides $6.9M tenant improvement allowance; additional $2.3M loan at 6% interest for improvements.","Base rent starts at $40.00/sq ft/year with 2.5% annual escalations; security deposit $700,000.","Three 5-year renewal options; rent for option terms determined by fair market value appraisal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}